BioCentury
ARTICLE | Distillery Therapeutics

Oligoadenylate-conjugated benzimidazole-based miR-210 inhibitor for breast cancer

June 7, 2019 10:46 PM UTC

INDICATION: Breast cancer...

BCIQ Company Profiles

Scripps Research

BCIQ Target Profiles

MicroRNA-210 (miR-210)